Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.

[1]  P. Ponikowski,et al.  Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.

[2]  R. McKelvie,et al.  CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. , 2021, The Canadian journal of cardiology.

[3]  G. Filippatos,et al.  Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. , 2021, Journal of the American College of Cardiology.

[4]  J. Silva-Cardoso,et al.  The Future of Telemedicine in the Management of Heart Failure Patients , 2021, Cardiac failure review.

[5]  L. Lund,et al.  The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019 , 2021, European journal of heart failure.

[6]  C. Fonseca,et al.  Management of RAASi-associated hyperkalemia in patients with cardiovascular disease , 2021, Heart Failure Reviews.

[7]  P. Ponikowski,et al.  Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[8]  P. Ponikowski,et al.  Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry , 2021, ESC heart failure.

[9]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.

[10]  J. Bauersachs.  Heart failure drug treatment: the fantastic four , 2021, European heart journal.

[11]  G. Fonarow,et al.  2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.

[12]  H. Bueno,et al.  The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. , 2021, European heart journal.

[13]  J. McMurray,et al.  How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. , 2020, Circulation.

[14]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[15]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[16]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[17]  P. Ponikowski,et al.  Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.

[18]  D. DeMets,et al.  Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF , 2020, European Heart Journal.

[19]  G. Filippatos,et al.  Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction , 2020, Circulation.

[20]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.

[21]  G. Filippatos,et al.  SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.

[22]  P. Ponikowski,et al.  Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[23]  K. Dickstein,et al.  Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries , 2020, European journal of heart failure.

[24]  J. Barbetseas,et al.  Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients , 2020, Heart Failure Reviews.

[25]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[26]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[27]  L. Djoussé,et al.  Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study , 2020, BMC Cardiovascular Disorders.

[28]  E. Lonn,et al.  Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study , 2019, European journal of heart failure.

[29]  I. Piña,et al.  Clinical Implications of the New York Heart Association Classification , 2019, Journal of the American Heart Association.

[30]  B. Williams,et al.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial , 2019, The Lancet.

[31]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[32]  Christopher L. Roy,et al.  2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.

[33]  B. Pitt,et al.  The renin‐angiotensin‐aldosterone system and its suppression , 2019, Journal of veterinary internal medicine.

[34]  G. Filippatos,et al.  The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[35]  Akshay S. Desai,et al.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. , 2018, JACC. Heart failure.

[36]  X. Shang,et al.  Heart rate and outcomes in patients with heart failure with preserved ejection fraction , 2017, Medicine.

[37]  G. Filippatos,et al.  European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2017, European journal of heart failure.

[38]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[39]  G. Filippatos,et al.  European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2016, European journal of heart failure.

[40]  Akshay S. Desai,et al.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.

[41]  K. Anstrom,et al.  Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). , 2015, Circulation. Heart failure.

[42]  J. Omens,et al.  Mechanotransduction in cardiac hypertrophy and failure. , 2015, Circulation research.

[43]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[44]  J. Bourke,et al.  Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials , 2014, Heart.

[45]  W. Koch,et al.  Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy , 2013, Circulation research.

[46]  G. Breithardt,et al.  Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. , 2011, Journal of the American College of Cardiology.

[47]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[48]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[49]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[50]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[51]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[52]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[53]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[54]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[55]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[56]  A. Katz.  Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. , 1990, The New England journal of medicine.

[57]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[58]  D. Hutcheon,et al.  DIURETIC ACTION OF FUROSEMIDE. , 1965, Archives of internal medicine.

[59]  H. Kleinfelder.  [EXPERIMENTAL STUDIES AND CLINICAL TRIALS OF A NEW DIURETIC]. , 1963, Deutsche medizinische Wochenschrift.

[60]  J. Sprague,et al.  BENZOTHIADIAZINE DIOXIDES AS NOVEL DIURETICS , 1957 .

[61]  Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .

[62]  A Randomized Trial of /-Blockade in Heart Failure The Cardiac Insufficiency Bisoprolol Study (CIBIS) , 2005 .

[63]  P. Coulthard,et al.  Interventions for replacing missing teeth: different times for loading dental implants. , 2004, The Cochrane database of systematic reviews.

[64]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[65]  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1987, The New England journal of medicine.

[66]  R. Wenzel.  Diuretics in heart failure. , 1986, Lancet.